Abstract
Warfarin or dicoumarol prevents the production of functional clotting factors II, VII, IX and X. Navicular disease and thrombophlebitis are examples of equine thrombotic diseases in which warfarin has been used therapeutically. The initiation of anticoagulant therapy is relatively simple but attending veterinarians must be aware of the potential risks in order to minimize them. These risks include epistaxis, bleeding into the gastrointestinal tract and at the venipuncture site, and increased susceptibility to hematoma formation following local trauma. Vitamin K, especially vitamin K1 is a swift and specific antidote for warfarin toxicity.
Full text
PDF


Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BLAKE T. M., WOOD E. G., Jr, O'MOORE D., NEEL R. G. The vasodilating effects of coumarin derivatives. Am J Med Sci. 1962 May;243:598–602. doi: 10.1097/00000441-196205000-00008. [DOI] [PubMed] [Google Scholar]
- Colles C. M. A preliminary report on the use of warfarin in the treatment of navicular disease. Equine Vet J. 1979 Jul;11(3):187–190. doi: 10.1111/j.2042-3306.1979.tb01338.x. [DOI] [PubMed] [Google Scholar]
- Colles C. M., Hickman J. The arterial supply of the navicular bone and its variations in navicular disease. Equine Vet J. 1977 Jul;9(3):150–154. doi: 10.1111/j.2042-3306.1977.tb04009.x. [DOI] [PubMed] [Google Scholar]
- Colles C. M. Ischaemic necrosis of the navicular bone and its treatment. Vet Rec. 1979 Feb 17;104(7):133–137. doi: 10.1136/vr.104.7.133. [DOI] [PubMed] [Google Scholar]
- Deykin D. Warfarin therapy. 1. N Engl J Med. 1970 Sep 24;283(13):691–694. doi: 10.1056/NEJM197009242831307. [DOI] [PubMed] [Google Scholar]
- Feldman B. F. Coagulopathies in small animals. J Am Vet Med Assoc. 1981 Sep 15;179(6):559–563. [PubMed] [Google Scholar]
- HELLEMANS J., VORLAT M., VERSTRAETE M. SURVIVAL TIME OF PROTHROMBIN AND FACTORS VII, IX AND X AFTER COMPLETELY SYNTHESIS BLOCKING DOSES OF COUMARIN DERIVATIVES. Br J Haematol. 1963 Oct;9:506–512. doi: 10.1111/j.1365-2141.1963.tb05475.x. [DOI] [PubMed] [Google Scholar]
- Kahn R. A., Johnson S. A., DeGraff A. F. Effects of sodium warfarin on capillary ultrastructure. Am J Pathol. 1971 Oct;65(1):149–156. [PMC free article] [PubMed] [Google Scholar]
- Kakkar V. V. Prevention of venous thromboembolism. Clin Haematol. 1981 Jun;10(2):543–582. [PubMed] [Google Scholar]
- Mackie M. J., Douglas A. S. Oral anticoagulants in arterial disease. Br Med Bull. 1978 May;34(2):177–182. doi: 10.1093/oxfordjournals.bmb.a071489. [DOI] [PubMed] [Google Scholar]
- Mount M. E., Feldman B. F., Buffington T. Vitamin K and its therapeutic importance. J Am Vet Med Assoc. 1982 Jun 1;180(11):1354–1356. [PubMed] [Google Scholar]
- O'REILLY R. A., AGGELER P. M., LEONG L. S. STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN. J Clin Invest. 1963 Oct;42:1542–1551. doi: 10.1172/JCI104839. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Scott E. A., Byars T. D., Lamar A. M. Warfarin anticoagulation in the horse. J Am Vet Med Assoc. 1980 Dec 1;177(11):1146–1151. [PubMed] [Google Scholar]
- Scott E. A., Sandler G. A., Byars T. D. Warfarin: effects of intravenous loading doses and vitamin K on warfarin anticoagulation in the pony. Am J Vet Res. 1978 Dec;39(12):1888–1891. [PubMed] [Google Scholar]
- Scott E. A., Sandler G. A., Byars T. D. Warfarin: effects on anticoagulant, hematologic, and blood enzyme values in normal ponies. Am J Vet Res. 1979 Jan;40(1):142–146. [PubMed] [Google Scholar]
- Seller E. M., Lang-Sellers M. L., Koch-Weser J. Comparative warfarin binding to albumin from various species. Biochem Pharmacol. 1977 Dec 15;26(24):2445–2447. doi: 10.1016/0006-2952(77)90455-5. [DOI] [PubMed] [Google Scholar]
- WRIGHT H. P., KUBIK M. M., HAYDEN M. Recanalization of thrombosed arteries under anticoagulant therapy. Br Med J. 1953 May 9;1(4818):1021–1023. doi: 10.1136/bmj.1.4818.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]